Literature DB >> 7492088

Antibacterial activity of WY-49605 compared with those of six other oral agents and selection of disk content for disk diffusion susceptibility testing.

P C Fuchs1, A L Barry, D L Sewell.   

Abstract

The in vitro antimicrobial activity of an oral penem, WY-49605, was compared with those of six other oral antimicrobial agents against 598 bacterial isolates representing 51 different species. WY-49605 exhibited good activity against most gram-positive bacteria and members of the family Enterobacteriaceae. It had little activity against nonfermenting gram-negative bacilli, Enterobacter spp., Serratia spp., enterococci, Staphylococcus haemolyticus, and methicillin-resistant Staphylococcus aureus. Its activity was unaffected by the beta-lactamases of Neisseria gonorrhoeae, Haemophilus influenzae, and staphylococci. Disk diffusion susceptibility tests were performed with 5-, 10-, 15-, and 30-micrograms WY-49605 disks. The 5-micrograms disk is recommended, with tentative breakpoints of > or = 16 mm for susceptibility (MIC, < or = 2.0 microgram/ml) and < or = 12 mm for resistance (MIC, > or = 8.0 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492088      PMCID: PMC162765          DOI: 10.1128/AAC.39.7.1472

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.

Authors:  T Nishino; Y Maeda; E Ohtsu; S Koizuka; T Nishihara; H Adachi; K Okamoto; M Ishiguro
Journal:  J Antibiot (Tokyo)       Date:  1989-06       Impact factor: 2.649

2.  Susceptibility of anaerobic bacteria to ALP 201.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

3.  Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria.

Authors:  M Rylander; C E Nord; S R Norrby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

4.  Comparative antibacterial activity of the penem ALP 201.

Authors:  T Bergan; J da Fonseca
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

  4 in total
  4 in total

1.  Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa.

Authors:  Kiyomi Okamoto; Naomasa Gotoh; Takeshi Nishino
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay.

Authors:  K Okamoto; N Gotoh; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Ian A Critchley; James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Kate Murfitt; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  In Vitro Activity and Clinical Efficacy of Faropenem against Third-Generation Cephalosporin-Resistant Escherichia coli and Klebsiella pneumoniae.

Authors:  Kazuhiro Ishikawa; Yuki Uehara; Nobuyoshi Mori; Yumiko Mikami; Sayuri Tokioka; Daiki Kobayashi; Hisa Goke; Tatsuya Inukai; Aki Sakurai; Yohei Doi; Sayoko Kawakami; Shizuo Kayama; Motoyuki Sugai; Shigeki Nakamura
Journal:  Antimicrob Agents Chemother       Date:  2022-06-01       Impact factor: 5.938

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.